These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 2875745

  • 1. Effect of a 12-hour subcutaneous infusion of somatostatin-14 on blood glucose, insulin and glucagon levels in healthy subjects and insulin dependent diabetics.
    Villaume C, Beck B, Kolopp M, Toussain P, Debry G.
    Biomed Pharmacother; 1986; 40(2):61-4. PubMed ID: 2875745
    [Abstract] [Full Text] [Related]

  • 2. D-Trp8-D-Cys14-somatostatin--demonstration of its differential suppressive activity in juvenile diabetics.
    Neuhaus C, Kerner W, Maier V, Pfeiffer EF.
    Horm Metab Res Suppl; 1979; (8):115-8. PubMed ID: 395066
    [Abstract] [Full Text] [Related]

  • 3. Increased somatostatin response to glucagon in insulin-dependent diabetes mellitus.
    Kirilov G, Borissova AM, Abadjieva Z, Javorska N.
    Acta Physiol Pharmacol Bulg; 1991; 17(1):41-4. PubMed ID: 1687718
    [Abstract] [Full Text] [Related]

  • 4. Effect of twice daily subcutaneous administration of a long-acting somatostatin analog on 24-hour plasma glucose profiles in patients with insulin-dependent diabetes mellitus.
    Dimitriadis G, Gerich J.
    Horm Metab Res; 1985 Oct; 17(10):510-1. PubMed ID: 2866155
    [Abstract] [Full Text] [Related]

  • 5. Exogenous somatostatin raises plasma insulin levels in patients with insulin-dependent diabetes mellitus.
    Kollind M, Moberg E, Lins PE, Adamson U.
    Horm Metab Res; 1990 Nov; 22(11):581-3. PubMed ID: 1980258
    [Abstract] [Full Text] [Related]

  • 6. Insulin-mediated glucose disposal in type 1 (insulin-dependent) diabetic subjects treated by continuous subcutaneous or intraperitoneal insulin fusion.
    Beylot M, Khalfallah Y, Laville M, Sautot G, Dechaud H, Serusclat P, Berthezene F, Riou JP, Mornex R.
    Diabete Metab; 1987 Nov; 13(4):450-6. PubMed ID: 3315766
    [Abstract] [Full Text] [Related]

  • 7. Influence of insulin infusion kinetics of an artificial beta cell on blood glucose control in insulin-dependent diabetics.
    Kerner W, Beischer W, Maier V, Pfeiffer EF.
    Horm Metab Res Suppl; 1979 Nov; (8):71-80. PubMed ID: 395094
    [Abstract] [Full Text] [Related]

  • 8. Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects.
    Sherwin RS, Fisher M, Hendler R, Felig P.
    N Engl J Med; 1976 Feb 26; 294(9):455-61. PubMed ID: 1246330
    [Abstract] [Full Text] [Related]

  • 9. Postprandial paradoxical IGFBP-1 response in obese patients with Type 2 diabetes.
    Lehtihet M, Efendic S, Brismar K.
    Clin Sci (Lond); 2008 Sep 26; 115(5):167-74. PubMed ID: 18208402
    [Abstract] [Full Text] [Related]

  • 10. Blood glucose response to stress hormone exposure in healthy man and insulin dependent diabetic patients: prediction by computer modeling.
    Waldhäusl WK, Bratusch-Marrain P, Komjati M, Breitenecker F, Troch I.
    IEEE Trans Biomed Eng; 1992 Aug 26; 39(8):779-90. PubMed ID: 1354649
    [Abstract] [Full Text] [Related]

  • 11. Effect of intermittent endogenous hyperglucagonemia on glucose homeostasis in normal and diabetic man.
    Rizza R, Verdonk C, Miles J, Service FJ, Gerich J.
    J Clin Invest; 1979 Jun 26; 63(6):1119-23. PubMed ID: 447838
    [Abstract] [Full Text] [Related]

  • 12. The effect of three days of blood glucose normalization by means of an "artificial endocrine pancreas" on the concentrations of growth hormone, glucagon, and cortisol in juvenile diabetics.
    Schock A, Schultz M, Kerner W, Maier V, Pfeiffer EF.
    Horm Metab Res Suppl; 1979 Jun 26; (8):93-6. PubMed ID: 395097
    [Abstract] [Full Text] [Related]

  • 13. Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes.
    Raskin P, Unger RH.
    N Engl J Med; 1978 Aug 31; 299(9):433-6. PubMed ID: 683275
    [Abstract] [Full Text] [Related]

  • 14. Pre-exposure to glucagon impairs glucose recovery after insulin-induced hypoglycemia in man.
    Clausen N, Adamson U, Lins PE.
    Horm Metab Res; 1987 Aug 31; 19(8):375-8. PubMed ID: 2889657
    [Abstract] [Full Text] [Related]

  • 15. Hepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patients.
    Paquot N, Scheen AJ, Dirlewanger M, Lefèbvre PJ, Tappy L.
    Obes Res; 2002 Mar 31; 10(3):129-34. PubMed ID: 11886934
    [Abstract] [Full Text] [Related]

  • 16. Increase by somatostatin of the arginine induced rise in blood glucose in untreated insulin requiring diabetics.
    Waldhäusl W, Bratusch-Marrain P, Nowotny P.
    Endokrinologie; 1979 Mar 31; 73(3):323-7. PubMed ID: 499100
    [Abstract] [Full Text] [Related]

  • 17. [ Somatostatin in insulin-dependent diabetics and in pancreatectomized patients (author's transl)].
    Tragl KH, Pointner H, Kinast H, Flegel U, Deutsch E.
    Wien Klin Wochenschr; 1976 Sep 03; 88(16):530-2. PubMed ID: 1033640
    [Abstract] [Full Text] [Related]

  • 18. Route of administration as a factor in the selectivity of hormone suppression of a somatostatin analog in rats.
    Lien EL, Garsky VM.
    Horm Metab Res; 1981 Dec 03; 13(12):675-8. PubMed ID: 6119282
    [Abstract] [Full Text] [Related]

  • 19. Metabolic effects of somatostatin in maturity-onset diabetes.
    Tamborlane WV, Sherwin RS, Hendler R, Felig P.
    N Engl J Med; 1977 Jul 28; 297(4):181-3. PubMed ID: 876274
    [Abstract] [Full Text] [Related]

  • 20. Circulating platelet aggregates induced by somatostatin in insulin-dependent diabetic subjects.
    Coppola L, Giugliano D, Tirelli A, Misso L, Sgambato S, D'Onofrio F.
    Diabete Metab; 1980 Dec 28; 6(4):245-9. PubMed ID: 6110570
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.